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Abstract
Primary aldosteronism is the commonest form of hormone-related hypertension, with an estimated prevalence of 6–13% in the general 
population of hypertensive patients. Among patients with resistant hypertension, the proportion of PA is even higher. Through inten-
sive research in the field of basic science and the creation of large registries of patients with PA, it is possible to understand the effect of 
excess aldosterone not only on the cardiovascular system but also on the morphology and function of the other organs. Recent research 
has highlighted the differences in the regulation of calcium metabolism in patients with adrenal adenomas and PA. A lot of attention has 
been paid to the improvement of diagnostic methods, with particular emphasis on adrenal vein sampling, which is becoming increasingly 
important. In recent years there have been many publications on the prevalence of mutations in the potassium channel in patients with 
adrenal tumours and PA. A new form of familial hyperaldosteronism - FIII, has also been distinguished. Treatment of patients with PA 
still relies on the use of mineralocorticoid receptor antagonists or adrenalectomy, preferably preceded by a confirmation of aldosterone 
secretion lateralisation by adrenal vein sampling. (Endokrynol Pol 2013; 64 (4): 312–318)
Key words: adrenalectomy, adrenal vein sampling (AVS), aldosterone-to-renin ratio (ARR), KCNJ5 mutation, mineralocorticoid receptor 
antagonist, primary aldosteronism (PA), KCNJ5 mutation
Streszczenie
Pierwotny hiperaldosteronizm (PA) to najczęstsza postać nadciśnienia tętniczego uwarunkowanego hormonalnie, którego częstość 
w ogólnej populacji chorych na nadciśnienie tętnicze szacuje się na 6–13%. Wśród pacjentów z nadciśnieniem tętniczym opornym 
na leczenie odsetek chorych z PA jest jeszcze większy. Dzięki intensywnym badaniom z dziedziny nauk podstawowych i tworzeniu 
dużych rejestrów chorych z PA poznawany jest wpływ nadmiaru aldosteronu nie tylko na układ sercowo-naczyniowy, ale również na 
morfologię i funkcję pozostałych organów . W najnowszych badaniach podkreśla się odmienności w regulacji gospodarki wapniowej 
u chorych z gruczolakiem nadnercza i PA. Wiele miejsca poświęca się doskonaleniu metod diagnostyki, ze szczególnym uwzględnieniem 
cewnikowania żył nadnerczowych, które zyskuje coraz większe znaczenie. W ciągu ostatniego roku pojawiło się wiele publikacji doty-
czących występowania mutacji w kanale potasowym u chorych z guzem nadnercza i PA. Wyodrębniono również nową postać rodzinnie 
występującego hiperaldosteronizmu — FIII.
Leczenie pacjentów z PA w dalszym ciągu opiera się na stosowaniu antagonistów receptora dla mineralokortykoidów lub adrenalekto-
mii, optymalnie poprzedzonej potwierdzeniem lateralizacji w wydzielaniu aldosteronu za pomocą cewnikowania żył nadnerczowych. 
(Endokrynol Pol 2013; 64 (4): 312–318)
Słowa kluczowe: adrenalektomia, antagoniści receptora dla mineralokortykoidów, cewnikowanie żył nadnerczowych, mutacja genu KCNJ5, 
pierwotny hiperaldosteronizm, wskaźnik aldsteronowo-reninowy
Introduction
Primary aldosteronism as a form of secondary hyper-
tension was distinguished in 1954 by the American 
clinician Jerome Conn, who demonstrated a causal 
relationship between the development of hypertension 
and adrenocortical adenoma producing aldosterone. 
The first report on two patients in whom hypertension 
development was associated with adenomas of adrenal 
glomerulosa was presented in 1953 in the Polish Medical 
Weekly (Polski Tygodnik Lekarski) by the Polish physi-
cian Michał Lityński [1, 2].
Since then, especially over the past few years, there 
has been significant progress in understanding the 
pathogenesis and improving diagnosis and treatment 
of primary aldosteronism.
Many clinical centres dealing with primary aldoster-
onism create large international registries of patients, 
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which allow us to learn about the clinical profile and 
genetic background of this disease as well as to improve 
diagnosis and treatment, and ensure a long-term fol-
low-up. Great hopes are associated with studies on the 
genetic background of primary aldosteronism. In recent 
years there have been many publications evaluating the 
presence of mutations in the potassium channel in dif-
ferent groups of patients with primary aldosteronism. 
In this paper we present current views on the 
occurrence, pathogenesis, diagnosis and treatment 
of the commonest form of hormone-related arterial 
hypertension.
Incidence
Primary aldosteronism (PA) is the commonest form of 
hormone-related arterial hypertension [1, 2]. Therefore, 
it is not surprising that in the world literature much 
attention has been paid to the pathogenetic and clini-
cal aspects of this form of secondary hypertension. It 
is worth mentioning that expert recommendations 
concerning diagnosis and treatment of PA [3–6] have 
recently been published. 
In the present study we focus on the recent studies 
that have brought new elements to our knowledge of 
primary aldosteronism. There is an ongoing discussion 
concerning evaluation of the real prevalence of PA [7, 
8]. In recent studies the incidence of PA in the general 
population of hypertensive patients has been found to 
be 6–13% [7–9].
In a large prospective study of 1,180 Italian patients 
with newly diagnosed arterial hypertension (known 
by the acronym PAPY), primary aldosteronism was 
diagnosed in 11% of patients [9].
The literature emphasises that PA often affects 
patients with refractory arterial hypertension. The 
following studies, evaluating a relationship between 
refractory hypertension and primary aldosteronism, 
deserve particular attention:
Douma et al. evaluated the incidence of primary 
aldosteronism in 1,616 patients with refractory hy-
pertension. This study demonstrated that one in ten 
patients with refractory hypertension suffered from 
primary aldosteronism [10].
Calhoun et al. evaluated 88 patients with refractory 
hypertension; primary aldosteronism was diagnosed in 
every fifth patient (20%) [11].
Gallay et al. studied 90 patients with poorly con-
trolled arterial hypertension; secondary hypertension 
was diagnosed in 17% of patients [12].
Eide et al. evaluated 90 patients with refractory 
hypertension; primary aldosteronism was diagnosed 
in 23% of patients [13].
The results of the above studies indicate that the 
incidence of primary aldosteronism in patients with re-
fractory hypertension is in the range of 11–23% [10–13].
The results of studies carried out between 2009 
and 2012 in the Department of Hypertension at the 
Institute of Cardiology in Warsaw within the RESIST-
POL registry, which enrolled 204 patients with true 
refractory hypertension, should also be mentioned. 
Among the secondary causes of arterial hypertension, 
primary aldosteronism was commonest in this group 
of patients (in 16% of patients). A relationship between 
primary aldosteronism and obstructive sleep apnoea 
(OSA)/metabolic syndrome was also demonstrated [14].
“Endocrine Society Clinical Practice Guideline” 
presented the opinion, based on cross-sectional and 
prospective studies, that the incidence of PA in the 
general population of hypertensive patients and in 
those treated in specialist centres was more than 10% 
[4]. The Journal of Hypertension has presented an in-
teresting debate on primary aldosteronism led by two 
prominent experts in arterial hypertension: Kaplan and 
Funder [15, 16]. Kaplan is of the opinion that PA does 
not occur as often as observed in studies published in 
recent years, and the diagnosis of this disease is too 
complex and expensive to be applied in all patients 
with arterial hypertension. However, he recommends 
a wider use of mineralocorticoid receptor antagonists 
in the treatment of arterial hypertension [15]. Funder 
partially agrees with Kaplan, in particular with regard 
to the possibility of more frequent use of mineralocorticoid 
receptor antagonists, but he draws attention to progress 
in the diagnosis and treatment of PA, and the fact that 
patients with PA have a very high cardiovascular risk [16]. 
However, it should be remembered that eplerenone, the 
use of which is associated with a much better tolerance 
than the use of spironolactone, has been registered in 
the United States (but not in Europe) for the treatment 
of arterial hypertension, and soon generic formulations 
of this drug will also be available in this country [15, 16].
Pathogenesis and impact of aldosterone  
on cardiovascular complications
Primary aldosteronism is a form of arterial hyperten-
sion characterised by heterogeneous pathogenesis. The 
differences regard the nature of adrenal abnormalities, 
clinical manifestation and genetic predisposition.
In recent decades, dynamic studies have demon-
strated multiple biological properties of aldosterone, 
exceeding its classic effect on the water and electrolyte 
balance. It has been shown that aldosterone exerts 
proinflammatory effects, enhances formation of free 
oxygen radicals, promotes cardiac, vascular and renal 
fibrosis, activates TGF1 and PAI1, and influences the im-
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mune system [17–19]. Primary aldosteronism makes it 
possible to observe the clinical effects of excess produc-
tion of aldosterone on the system.
Noteworthy are the studies carried out by O. 
Steichen et al., involving 460 patients with PA. A higher 
incidence of heart failure (7.4% v. 3.6%), coronary heart 
disease (5.6% v. 1%), and atrial fibrillation was observed 
in these patients, compared to a group of 1,291 patients 
with essential hypertension [20].
Other studies have demonstrated a thicker intima-
media complex in the carotid arteries of PA patients, 
compared to patients suffering from essential hyper-
tension [21]. Attention should also be paid to studies 
that have shown a reduced arterial compliance, as-
sessed using carotid-femoral pulse wave velocity and 
increased aortic augmentation index, compared to 
patients suffering from essential hypertension. Surgical 
removal of the adrenal adenoma resulted in a reduction 
of arterial stiffness [22]. Studies carried out by Italian 
authors have demonstrated changes in the structure of 
small resistance arteries in PA patients [23, 24]. There 
are also observations indicating a higher incidence rate 
of microalbuminuria in patients with PA [25, 26]. There 
are also reports on a higher prevalence of metabolic 
disorders. Studies that demonstrated a higher incidence 
of metabolic syndrome in PA patients are also worth 
mentioning [27, 28]. It is important to stress that the 
mechanisms underlying the observed correlation have 
not been elucidated. Studies that revealed increased 
levels of oxidative stress and myocardial fibrosis factors, 
compared to patients with essential hypertension [29, 
30], should also be mentioned.
Primary aldosteronism is very rarely accompanied 
by malignant hypertension [31, 32]. A case of a young 
PA male patient with malignant hypertension and 
prominent left ventricular hypertrophy has recently 
been described [33]. Surgical removal of the adrenal 
adenoma resulted in normalisation of blood pressure, 
regression of left ventricular hypertrophy and systolic 
function improvement. The authors believe that both 
severe hypertension and direct damaging effects of 
aldosterone, as two independently acting factors, have 
caused prominent left ventricular hypertrophy [33].
It has been suggested that mineralocorticoid recep-
tors present in cardiomyocytes may contribute to myo-
cardial remodelling. Fluid retention in cardiomyocytes 
influenced by aldosterone, and intracardiac volume 
increase, accompanied by increased intramural stress 
— in-wall-stress — should also be taken into considera-
tion [17, 34].
Studies aimed to verify the hypothesis postulating 
the effect of aldosterone on the secretion of parathy-
roid hormone (PTH) are also worth mentioning. Pilz 
et al. observed higher levels of PTH and lower serum 
calcium levels in PA patients, compared to patients with 
essential hypertension; PTH levels were significantly 
reduced as a result of the PA treatment (surgery or ad-
ministration of mineralocorticoid receptor antagonist) 
[35]. Another study which included 44 patients with 
PA in the course of adrenocortical adenoma, and 61 
patients with essential hypertension, demonstrated that 
PA patients had also significantly elevated plasma PTH 
levels (31%), compared to patients suffering from es-
sential hypertension. Surgical removal of the adenoma 
resulted in normalisation of plasma PTH levels and 
increased concentration of ionised calcium in serum; 
the results of another study involving the same group 
also indicated that elevated serum PTH levels might be 
useful in the differentiation of a PA type [36, 37].
Diagnostic methods
Aldosterone-to-renin ratio (ARR)
According to ‘An Endocrine Society Clinical Practice 
Guideline’, determination of aldosterone-to-renin ratio 
is currently the most reliable screening test for PA. The 
ratio of aldosterone to plasma renin activity (PRA), 
expressed in ng/dL and ng/mL/h, respectively, which 
exceeds 30, indicates the diagnosis of PA [4].
It is believed that aldosterone-to-renin ratio, like 
all biochemical screening tests, is charged with false-
positive and false-negative results [38]. Thus, much 
emphasis has been placed on the importance of factors 
that may affect the reliability of this test. According to 
Kaplan, the commonest cause of false-positive test re-
sults is a low PRA value, which occurs in approximately 
30% of patients with arterial hypertension [15].
Antihypertensive drugs may have a great impact 
on the result of ARR measurement [39]. In patients 
with severe hypertension, withdrawal of these drugs 
is often not possible. It is connected with the risk of 
serious cardiovascular complications [5]. It has been 
recently reported that anti-depressants reduce the 
value of ARR [40], while oral contraceptives increase 
this value [41]. One should bear in mind that some 
antihypertensive drugs may only slightly affect the 
reliability of the test. These include hydralazine, 
verapamil or doxazosin [4].
The lower detection limit of plasma renin activity 
has a great impact on the value of ARR. It can vary 
for individual laboratory kits. The threshold value of 
PRA detection should not be less than 0.2 ng/mL/h. 
Progress in the methods for PRA measurement have 
allowed the determination of its values below 0.6 ng/
mL/h. The difference between 0.1 and 0.2 ng/mL/h can 
be physiologically negligible, but it doubles the value 
of aldosterone-to-renin ratio [1, 2, 3].
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Adrenal Vein Sampling (AVS)
Adrenal vein sampling is the method of choice in the dif-
ferentiation of a PA. It enables identification of the source 
of increased secretion of aldosterone. This is important 
because the detection of adrenocortical adenoma secret-
ing the excess of aldosterone is an indication for surgical 
treatment, whereas bilateral adrenal hyperplasia is an 
indication for conservative treatment [4].
“An Endocrine Society Clinical Practice Guideline” 
presents an opinion that AVS is the gold standard in 
the diagnosis of lateralisation of changes in the adrenal 
glands in patients with PA. It was emphasised that the 
test can be performed only in specialist centres by prop-
erly trained staff [4]. In recent years, there have been 
many publications devoted to assessing the diagnostic 
usefulness of this method [42–49].
It is worth mentioning that in a retrospective study 
evaluating surgical treatment in 168 patients, the diag-
nosis of adrenocortical adenomas was established by 
means of computed tomography or AVS. Normalised or 
improved blood pressure control was achieved in 77% 
of patients with unilateral adenoma. The usefulness of 
AVS in patients with a typical clinical manifestation of 
PA, in whom visualisation revealed no changes in the 
adrenal glands, has been demonstrated [50].
We should also remember the studies carried out by 
Italian authors, which were devoted to the assessment 
of the diagnostic value of AVS. The study included 151 
consecutive patients who underwent AVS; the limit 
value of laterality index for the differentiation between 
unilateral changes (adenoma) and bilateral adrenal 
hyperplasia was assessed. The study demonstrated 
the usefulness of this index in the differentiation of 
changes, highlighted the safety of the method and the 
importance of great experience of the staff performing 
the test [51].
While discussing the diagnostic utility of AVS, we 
cannot overlook the meta-analysis published in 2009 
[52]. This demonstrated that a unilateral change in the 
adrenal glands observed during imaging examination 
was consistent with the result of AVS only in 67% of 
patients. The interpretation of the results was compli-
cated by the fact that the results of surgical treatment 
were not given. Therefore, it is not possible to decide 
which of these methods was reliable in cases where the 
results of both examinations were not consistent [52].
Extensive studies carried out by Italian authors are 
also worth mentioning. They concerned patients with 
adrenocortical adenomas treated surgically. The authors 
demonstrated sensitivity and specificity of AVS of 80% 
and 75%, respectively [53].
There are also observations indicating the disap-
pearance of humoral changes in almost 100% of patients 
with adrenal adenoma treated surgically. Only 20% of 
patients underwent AVS before surgery; in the remain-
ing patients, adrenal adenoma was diagnosed on the 
basis of imaging examinations [54].
Plouin et al. are of the opinion that the diagnostic 
usefulness of adrenal venous sampling can be assessed 
based on its ability to predict the effectiveness of sur-
gical treatment. No differences were observed for the 
results of surgical treatment between patients in whom 
AVS was performed routinely and patients in whom this 
examination was performed selectively (39% v.42%). 
The authors have stated that the abovementioned data 
suggests a more critical assessment of the usefulness of 
AVS. Selective rather than routine AVS can reduce the 
nuisance value of the examination, without any serious 
damage to the patient [55].
According to American experts, who expressed 
their opinion in published guidelines, AVS should be 
performed more frequently. Regarding the fact that 
these guidelines are based on poorly documented 
(according to Evidence Based Medicine) studies, AVS 
may be skipped in selected cases with a typical image 
of adenoma during visualisation [6].
Genetic tests
In recent years, significant progress in understanding the 
genetic background of PA has been observed [56–58]. In 
2011, Science published an innovative work by Choi et al. 
concerning genetic aspects of PA in relation to adrenocorti-
cal adenoma [59]. The authors demonstrated a mutation 
of KCNJ5 gene encoding the potassium channel Kir 3.4 
in eight out of 22 adenomas obtained from patients with 
PA (36%). The mutation was more common in younger 
patients and in women. Patients with a detected mutation 
were characterised by a higher aldosterone-to-renin rate 
compared to other patients [59].
In a large study based on material collected in nine 
clinical centres in France, Germany and Italy, somatic 
mutations of KCNJ5 gene were found in 34% of adreno-
cortical tumours; a higher incidence of KCNJ5 muta-
tions was observed in younger patients and in women. 
In patients with a somatic mutation of KCNJ5 gene 
within the adenoma, higher plasma aldosterone levels 
were observed than in patients without mutations. In all 
the patients with adenomas and bilateral hyperplasia in 
the course of PA, no germinal mutations of KCNJ5 were 
found [60]. However, in studies conducted in Australia 
and England, which included 73 patients with PA and 
adrenocortical adenomas, in 41% of tumours somatic 
mutations of KCNJ5 gene were found. Tumours with 
somatic mutations of KCNJ5 gene were significantly 
larger (1.61 v. 1.04 cm). The presence of somatic muta-
tions of KCNJ5 gene was associated with the lack of 
aldosterone level response to verticalisation, which 
according to the authors might indicate a different 
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phenotype of tumours with these mutations [61]. We 
should also take into account the opinion expressed by 
many authors that somatic mutations of the potassium 
channel gene KCNJ5 are just one of many stages of the 
complex pathogenesis of aldosterone-secreting adrenal 
adenomas [56, 57, 62, 63]
Germinal mutations of KCNJ5 gene were also found 
in the newly separated severe form of PA — familial type 
III PA [59]. In another work, mutations of KCNJ5 gene 
associated with the familial type III PA were described. 
The authors demonstrated that in contrast to previous 
descriptions, mutations of this gene may be associated not 
just with a very severe course of the disease [64]. In another 
paper describing families affected by the familial type III 
PA, it has been shown that the site of KCNJ5 mutations 
has a direct impact on the functioning of the potassium 
channel and course of the disease, which can be very 
severe (requiring bilateral adrenalectomy) or mild (easily 
controlled arterial hypertension, no anatomical changes 
in the adrenal glands) [65].
Treatment
Treatment of primary aldosteronism should be initiated 
as early as possible, in order to prevent cardiovascular, 
renal and cerebral complications, caused by excess 
aldosterone.
Interesting results were obtained from investiga-
tions carried out under the TAIPAI Study. They were 
aimed to analyse the impact of surgical treatment of 
PA associated with adrenocortical adenoma on the re-
gression of myocardial fibrosis. This prospective study 
included 20 patients with PA treated from 2006 to 2008. 
The control group consisted of 20 patients with essential 
hypertension. The authors measured the concentration 
of carboxy-terminal propetide of type 1 procollagen — 
PICP, which is an indicator of the formation of type 1 
collagen. In addition, echocardiography was performed 
using ultrasonic tissue characterisation by cyclic vari-
ations of integrated backscatter (CVIBS). Patients with 
PA had higher systolic and diastolic blood pressure, 
higher plasma aldosterone concentration, and higher 
aldosterone-to-renin ratio than patients with essential 
hypertension. In addition, they were characterised by 
a higher left ventricular mass index. In these patients, 
significantly lower CVIBS values and significantly 
higher PICP levels were observed compared to patients 
suffering from essential hypertension, which could 
indicate increased myocardial fibrosis. One year after 
the surgical removal of the adrenal adenoma, increased 
CVIBS values and decreased plasma PICP concentra-
tions were observed [66].
In conclusion, the authors state that the obtained 
results demonstrated, for the first time in the literature, 
the regression of myocardial fibrosis in patients with PA 
after surgical removal of adrenal adenoma. An interest-
ing observation indicated a correlation between CVIBS 
and plasma aldosterone levels/plasma renin activity 
rather than blood pressure. This may indicate that 
myocardial fibrosis is more dependent on hormonal 
changes than on high blood pressure [66].
French authors conducted studies assessing the 
impact of surgical removal of adrenal adenoma in PA 
patients on arterial blood pressure and antihypertensive 
treatment [67]. The study included 156 consecutive pa-
tients with adrenocortical adenoma, treated surgically 
at a single clinical centre from 2001 to 2009. Adrenal-
ectomy resulted in normalisation of blood pressure in 
68 patients (44%). In the remaining patients, a decrease 
in blood pressure of 21–31% and a reduction in the 
number of used antihypertensive drugs by 1 (scale 
1–3) was observed. The achieved hypotensive effect of 
surgical treatment was more pronounced in patients 
with higher blood pressure values in the preoperative 
period and a higher concentration of sodium in plasma. 
Achieving normalisation of blood pressure was less like-
ly in patients with a longer duration of hypertension, 
higher blood pressure values, more antihypertensive 
drugs used, and reduced urinary aldosterone excretion. 
The authors are of the opinion that patients with PA and 
severe arterial hypertension receive substantial benefit 
from surgical treatment. However, normalisation of the 
blood pressure is less likely [67].
Studies based on the German register of primary 
aldosteronism are particularly noteworthy [68]. Mortal-
ity was assessed in 350 patients with PA treated at three 
clinical centres in Germany. The control group consisted 
of 600 individuals with normal blood pressure, and 
600 hypertensive patients from population studies in 
Germany. After diagnosis and initiation of therapy, PA 
patients were followed from 1994. The analysis of the 
results was carried out in 2009 and 2010. The analysed 
parameters were evaluated in the 2:1 system. Analysis 
of the results showed that the overall mortality in PA 
patients did not differ from mortality in patients with 
essential hypertension. Cardiovascular events were 
the main cause of death in patients with PA — 50% v. 
34% in hypertensive patients in the control group [66].
The obtained results suggest that cardiovascular 
deaths are more common in treated PA patients during 
a long-term follow-up. In PA patients, age, coexisting 
diabetes and coronary artery disease were associated 
with a higher risk of death. The abovementioned stud-
ies assessed, for the first time in literature, mortality in 
treated PA patients during a long-term follow-up. It 
should be stressed that Kaplan-Meier survival curves 
were deviated in PA patients after six years. The au-
thors emphasise the need for a long-term follow-up of 
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treated PA patients and strict control of coexisting risk 
factors. This applies especially to patients whose high 
blood pressure persisted after adrenalectomy, or whose 
treatment with aldosterone antagonists was not entirely 
satisfactory [68].
As mentioned before, the method of choice in patients 
with idiopathic adrenal hyperplasia is pharmacological 
treatment with spironolactone or eplerenone [1–4].
A study aimed to compare the antihypertensive ef-
ficacy of both aldosterone antagonists in patients with 
PA should also be mentioned. This was a prospective, 
randomised and open study lasting for 24 weeks, which 
included 34 patients with bilateral adrenal hyperplasia. 
Eplerenone was used at a dose of 50–200 mg/day, and 
spironolactone at a dose of 50–400 mg/day. The results 
demonstrated that both medicines had comparable 
antihypertensive effects [69].
Results of research carried out by Parthasarathy 
et al. should also be noted. This was a randomised, 
double-blind, multicentre trial involving two parallel 
and balanced groups of patients. The study included 
141 patients with primary aldosteronism. For 16 weeks 
the subjects received eplerenone in increasing doses 
from 100 to 300 mg/day and spironolactone in doses 
from 75 to 225 mg/day. The hypotensive effect was more 
pronounced in patients treated with spironolactone 
than in those treated with eplerenone. Despite a more 
frequent occurrence of gynaecomastia, mastodynia and 
hyperkalaemia in patients receiving spironolactone, the 
overall incidence of undesirable effects was comparable 
in both treatment groups [70].
It is also worth mentioning that some observations 
have demonstrated a similar effectiveness of surgi-
cal treatment (adenoma) and pharmacotherapy with 
spironolactone. However, reports on the effectiveness of 
pharmacological treatment in PA patients in the course 
of adrenal adenomas are limited, and adrenalectomy 
remains the method of choice [71–73].
Summary
In conclusion, we must emphasise the constant pro-
gress in the improvement of diagnostic methods and 
treatment of primary aldosteronism. In particular, 
many achievements in this area can be expected from 
genetic studies.
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